A sense of change on all fronts pervaded the Clinical Trials on Alzheimer’s Disease conference. Scientists shared their early experiences of what works and what does not as they begin trials with newly defined cohorts, new diagnostic criteria, and new outcomes.
After lighting up microglia in mouse models of AD, a tracer is headed for clinical trials.
Protein touted as a peripheral monocyte receptor that worsens amyloid plaque pathology in transgenic mice.
A micro-immunoelectrode allows researchers measure Aβ levels in the interstitial fluid of mice every 30 seconds.
Basic preclinical discoveries keep meeting vibrant for neurodegenerative disease researchers from around the world
At Duke University, researchers discussed how injected stem cells might be tracked and used to treat neurodegenerative diseases.
Whether by themselves or in the company of mutations that cause frontotemporal dementia, microRNAs may play a hand in driving disease.
At ICFTD, researchers proposed new genes and explored genetic differences that contribute to the vast diversity of FTD clinical presentations.
In debating how C9ORF72 causes neurodegeneration, researchers struggle to connect cell-culture results with divergent patterns of human disease.
FORUM Pharmaceuticals announced that its histone deacetylase inhibitor has passed a Phase 1 trial, and will advance to Phase 2 immediately. It was one of two trials presenting data on active investigational drugs at ICFTD.
Using physiological measurements, researchers are tracing behavior changes in frontotemporal dementia back to crumbling neural circuitry.
Not to be outdone by ongoing FTLD cohort studies underway mostly in Europe, U.S.-Canadian studies are now forging structured networks to track presymptomatic and symptomatic cases and to engage a panoply of funders and advocacy groups in a clinical trials initiative.
You might not think it possible to assemble large, longitudinal cohorts of loyal study subjects for rare dementias marked by apathy and emotional blunting. Think again—at the International Conference for Frontotemporal Dementia, researchers showed that they just did it.
Confirming hints from case reports, the Genetic FTD Initiative, a European-Canadian frontotemporal dementia network, shows which brain areas change long before tau, progranulin, and C9ORF72 mutation carriers become symptomatic.
Scientific advances fire up researchers at FTD meeting in a dreary Vancouver.